Popular search terms:
Search Results
31 results found-
Our scientists are recognized for their contributions to developing breakthrough medicines that have the potential to help patients worldwide.
https://www.cslbehring.com.au/research-and-development/research-and-development-capabilities -
Support was provided to HFA to support training for youth leaders and mentors in the bleeding disorders community, and advancing HFA's digital Haemophilia Foundation Australia footprint with youth.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/transparency-reports/csl-behring-2020-health-consumer-organisation-support.pdf -
CSL Behring is a global biotech company leading the way to deliver innovative therapies for rare and serious diseases.
https://www.cslbehring.com.au/our-company -
CSL Behring provides protein-based therapies for bleeding disorders, critical care, pulmonary disease, and other rare illnesses.
https://www.cslbehring.com.au/products -
CSL Behring is committed to advancing scientific knowledge, fostering excellence, and supporting future medical researchers.
https://www.cslbehring.com.au/research-and-development/awards-and-grants/professor-heimburger-award -
It does not consult your doctor or contain complete information Individuals with factor IX levels haemophilia treatment centre.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/monofixvf-au-cmi-300.pdf -
4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS MonoFIX®-VF is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia B. MonoFIX®-VF is not indicated for the treatment of factor II, VII or X deficiencies because it does not contain therapeutic levels of these coagulation factors.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/monofixvf-au-pi-400.pdf